18 0 2 0 2 B-lower_bound
- 2 3 2 3 O
65 3 5 3 5 B-upper_bound
year 6 10 6 10 I-upper_bound
old 11 14 11 14 O
male 15 19 15 19 B-gender
and 20 23 20 23 I-gender
female 24 30 24 30 I-gender
patients 31 39 31 39 I-gender
with 40 44 40 44 O
primary 45 52 45 52 B-chronic_disease
cervical 53 61 53 61 I-chronic_disease
dystonia 62 70 62 70 I-chronic_disease

ALT 0 3 71 74 B-clinical_variable
or 4 6 75 77 O
AST 7 10 78 81 B-clinical_variable
greater 11 18 82 89 O
than 19 23 90 94 O
twice 24 29 95 100 B-lower_bound
normal 30 36 101 107 I-lower_bound
value 37 42 108 113 I-lower_bound

Active 0 6 114 120 O
depression 7 17 121 131 B-chronic_disease

Active 0 6 132 138 B-chronic_disease
infection 7 16 139 148 I-chronic_disease

Active 0 6 149 155 O
psychosis 7 16 156 165 B-chronic_disease

Cognitive 0 9 166 175 B-treatment
impairment 10 20 176 186 I-treatment

Creatinine 0 10 187 197 B-clinical_variable
clearance 11 20 198 207 I-clinical_variable
< 21 22 208 209 O
50ml 23 27 210 214 B-upper_bound
/ 27 28 214 215 I-upper_bound
min 28 31 215 218 I-upper_bound

Galactose 0 9 219 228 B-chronic_disease
intolerance 10 21 229 240 I-chronic_disease
, 21 22 240 241 O
the 23 26 242 245 O
Lapp 27 31 246 250 B-chronic_disease
lactase 32 39 251 258 I-chronic_disease
deficiency 40 50 259 269 I-chronic_disease
or 51 53 270 272 O
glucose 54 61 273 280 B-chronic_disease
- 61 62 280 281 I-chronic_disease
galactose 62 71 281 290 I-chronic_disease
malabsorption 72 85 291 304 I-chronic_disease

Hamilton 0 8 305 313 B-clinical_variable
Depression 9 19 314 324 I-clinical_variable
Rating 20 26 325 331 I-clinical_variable
Scale 27 32 332 337 I-clinical_variable
( 33 34 338 339 I-clinical_variable
HDRS 34 38 339 343 I-clinical_variable
) 38 39 343 344 I-clinical_variable
score 40 45 345 350 I-clinical_variable
â‰¥ 46 47 351 352 O
12 48 50 353 355 B-lower_bound

Hypersensitivity 0 16 356 372 O
to 17 19 373 375 O
perampanel 20 30 376 386 B-allergy_name

Montreal 0 8 387 395 B-clinical_variable
Cognitive 9 18 396 405 I-clinical_variable
assessment 19 29 406 416 I-clinical_variable
( 30 31 417 418 I-clinical_variable
MOCA 31 35 418 422 I-clinical_variable
) 35 36 422 423 I-clinical_variable
< 37 38 424 425 O
26 39 41 426 428 B-upper_bound

Secondary 0 9 429 438 B-chronic_disease
cervical 10 18 439 447 I-chronic_disease
dystonia 19 27 448 456 I-chronic_disease

Significant 0 11 457 468 O
renal 12 17 469 474 B-chronic_disease
dysfunction 18 29 475 486 I-chronic_disease

Subject 0 7 487 494 O
may 8 11 495 498 O
be 12 14 499 501 O
untreated 15 24 502 511 O
with 25 29 512 516 O
botulinum 30 39 517 526 B-treatment
toxin 40 45 527 532 I-treatment

Subjects 0 8 533 541 O
may 9 12 542 545 O
be 13 15 546 548 O
on 16 18 549 551 O
stable 19 25 552 558 O
anti 26 30 559 563 B-treatment
- 30 31 563 564 I-treatment
dystonia 31 39 564 572 I-treatment
treatment 40 49 573 582 I-treatment
( 50 51 583 584 O
for 51 54 584 587 O
at 55 57 588 590 O
least 58 63 591 596 O
one 64 67 597 600 B-lower_bound
month 68 73 601 606 I-lower_bound
) 73 74 606 607 O
including 75 84 608 617 O
anticholinergics 85 101 618 634 B-treatment
, 101 102 634 635 O
baclofen 103 111 636 644 B-treatment
, 111 112 644 645 O
and 113 116 646 649 O
anxiolytics 117 128 650 661 B-treatment
including 129 138 662 671 O
benzodiazepines 139 154 672 687 B-treatment

Women 0 5 688 693 B-gender
who 6 9 694 697 O
are 10 13 698 701 O
pregnant 14 22 702 710 B-pregnancy
or 23 25 711 713 O
plan 26 30 714 718 B-pregnancy
to 31 33 719 721 I-pregnancy
become 34 40 722 728 I-pregnancy
pregnant 41 49 729 737 I-pregnancy

active 0 6 738 744 O
liver 7 12 745 750 B-chronic_disease
disease 13 20 751 758 I-chronic_disease

barbiturates 0 12 759 771 B-treatment

cholestasis 0 11 772 783 B-chronic_disease

cirrhosis 0 9 784 793 B-chronic_disease

efavirenz 0 9 794 803 B-treatment

elevated 0 8 804 812 B-clinical_variable
bilirubin 9 18 813 822 I-clinical_variable

glucocorticoids 0 15 823 838 B-treatment
( 16 17 839 840 O
other 17 22 840 845 O
than 23 27 846 850 O
topical 28 35 851 858 B-treatment
usage 36 41 859 864 I-treatment
) 41 42 864 865 O

hepatitis 0 9 866 875 B-chronic_disease

modafinil 0 9 876 885 B-treatment

nevirapine 0 10 886 896 B-treatment

pioglitazone 0 12 897 909 B-treatment

rifabutin 0 9 910 919 B-treatment

treated 0 7 920 927 O
with 8 12 928 932 O
botulinum 13 22 933 942 B-treatment
toxin 23 28 943 948 I-treatment
but 29 32 949 952 O
who 33 36 953 956 O
are 37 40 957 960 O
at 41 43 961 963 O
least 44 49 964 969 O
8 50 51 970 971 B-lower_bound
weeks 52 57 972 977 I-lower_bound
( 58 59 978 979 O
+ 59 60 979 980 O
1 61 62 981 982 O
week 63 67 983 987 O
) 67 68 987 988 O
from 69 73 989 993 O
a 74 75 994 995 O
previous 76 84 996 1004 O
injection 85 94 1005 1014 O

who 0 3 1015 1018 O
have 4 8 1019 1023 O
experienced 9 20 1024 1035 O
an 21 23 1036 1038 O
insufficient 24 36 1039 1051 O
response 37 45 1052 1060 O
to 46 48 1061 1063 O
botulinum 49 58 1064 1073 B-allergy_name
toxin 59 64 1074 1079 I-allergy_name
in 65 67 1080 1082 O
the 68 71 1083 1086 O
opinion 72 79 1087 1094 O
of 80 82 1095 1097 O
the 83 86 1098 1101 O
enrolling 87 96 1102 1111 O
investigator 97 109 1112 1124 O

women 0 5 1125 1130 B-gender
who 6 9 1131 1134 O
are 10 13 1135 1138 O
breastfeeding 14 27 1139 1152 O

